Gross Profit Analysis: Comparing Teva Pharmaceutical Industries Limited and Halozyme Therapeutics, Inc.

Teva vs. Halozyme: A Decade of Gross Profit Trends

__timestampHalozyme Therapeutics, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 20145260200011056000000
Thursday, January 1, 201510581200011356000000
Friday, January 1, 201611348500011859000000
Sunday, January 1, 201728546100010825000000
Monday, January 1, 20181417260008296000000
Tuesday, January 1, 20191504460007536000000
Wednesday, January 1, 20202242270007725000000
Friday, January 1, 20213618970007594000000
Saturday, January 1, 20225208120006973000000
Sunday, January 1, 20236368920007646000000
Monday, January 1, 20248559070008064000000
Loading chart...

Unveiling the hidden dimensions of data

Gross Profit Trends: Teva vs. Halozyme

In the ever-evolving pharmaceutical industry, understanding financial health is crucial. This analysis compares the gross profit trends of Teva Pharmaceutical Industries Limited and Halozyme Therapeutics, Inc. from 2014 to 2023. Over this period, Teva's gross profit has seen a decline of approximately 31%, from a peak in 2016 to a low in 2022. In contrast, Halozyme has experienced a remarkable growth of over 1,100%, showcasing its dynamic expansion strategy.

Key Insights

  • Teva's Challenges: Teva's gross profit decreased significantly, reflecting industry challenges and competitive pressures.
  • Halozyme's Growth: Halozyme's consistent upward trajectory highlights its innovative approach and market adaptability.

This decade-long comparison underscores the contrasting financial journeys of these two pharmaceutical giants, offering valuable insights into their strategic directions and market positions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025